Mestag Therapeutics appoints new chief scientific officer

Mestag Therapeutics, a leading biotech company specialising in fibroblast immunology for inflammatory disease and cancer, has appointed Dr Matthew Sleeman as chief scientific officer.

With over 20 years of experience in R&D, Dr Sleeman has led the development of six FDA-approved monoclonal antibodies and more than 20 others currently in clinical trials. 

He joins Mestag from Regeneron, where he served as vice president of Research, overseeing immunology and inflammation research. 

His leadership contributed to the success of key products like Dupixent®, Kevzara® and Libtayo®.

Prior to Regeneron, Dr. Sleeman advanced multiple programmes at MedImmune and Cambridge Antibody Technology, helping secure the $1.3 billion acquisition of CAT by AstraZeneca in 2006. 

Dr. Sleeman said: “Over the last two decades, I have dedicated my career to advancing impactful antibody therapeutics, led by new biological insights that deepen our understanding of disease pathogenesis.

“Mestag’s compelling discoveries in fibroblast immunology, together with a unique portfolio of antibodies, offer an exciting opportunity to bring important new therapeutics to patients.

“I am energised to join the team and contribute to the development of a new class of therapeutics in inflammatory disease and cancer.”

Susan Hill, chief executive Mestag, added: “Matt is an experienced and highly respected R&D leader in the immunology and cancer biology field with an outstanding track record in the advancement of multiple commercialised antibody therapies.

“He joins us at an exciting time, as our pipeline of agonist antibody programs is poised to enter the clinic, we build our future portfolio of fibroblast immunology programmes, and we explore novel targets through our proprietary RAFT platform and in partnership with MSD.

“His extensive expertise in the development of antibody-based therapeutics, combined with a deep insight into inflammatory disease and cancer biology is ideally suited to our fibroblast immunology focus.

“We are delighted to welcome him to Mestag.”

Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →